NASH registry study aims to map disease in chinese patients
NCT ID NCT06123858
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This study was designed to collect information about Chinese patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Researchers planned to track how the disease is diagnosed and treated in real-world clinics, and to understand patients' knowledge and beliefs about NASH. The study was terminated, so results may be limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,122 people
The number who actually took part.
- Started
-
Nov 2023
- Finished
-
Oct 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects with NASH and fibrosis.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: (1) Subjects must be between 18 and 75 years old when signing the informed consent form, and must have the ability to sign the consent form independently; (2) NASH patients who meet one of the following conditions: 1. Liver biopsy was performed within 24 months before enrollment, and the pathological diagnosis was NASH and the fibrosis stage was F2 or above; 2. FibroScan-AST (FAST) score ≥ 0.30 within 24 months before enrollment; 3. There are any of the following evidences of fatty liver 1. Controlled attenuation parameter (CAP) \> 285 dB/m within 24 months before enrollment; 2. Liver ultrasonography showed fatty liver within 24 months before enrollment; 3. Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) examination within 24 months before enrollment showed liver fat fraction ≥ 5%; and any of the following evidence of liver fibrosis <!-- --> 1. Liver stiffness measurement (LSM) ≥ 7.5kPa by vibration-controlled transient elastography (VCTE) within 24 months before enrollment; 2. The elasticity value of magnetic resonance elastography (MRE) examination within 24 months before enrollment is ≥2.93kPa; 3. If there is no liver biopsy and no liver elastography equipment is available in the research center, FIB-4\>1.3 (under 65 years old) or\>2 (over 65 years old) within 3 months before enrollment. Exclusion Criteria: 1. History of liver transplantation; 2. Patients with bleeding tendency or coagulation dysfunction (for example, bleeding tendency, such as hemophilia, suspected hemangioma or suspected hydatid infection); 3. Exclude liver diseases caused by the following causes: alcoholic steatohepatitis, drug-induced, viral or autoimmune hepatitis, primary hemochromatosis, α1-antitrypsin deficiency, hepatolenticular degeneration, hypothyroidism, inflammatory bowel disease, Cushing's syndrome, celiac disease, β lipoprotein deficiency, lipoatrophic diabetes mellitus, Mauriac syndrome, hypopituitarism, hypogonadism, polycystic ovarian syndrome; 4. Have a history of malignant tumors in the past 5 years, excluding malignant tumors that have been cured by the investigator's judgment; 5. Pregnant or lactating women.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH with fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Beijing, China
-
Research Site
Changchun, China
-
Research Site
Chengdu, China
-
Research Site
Fuzhou, China
-
Research Site
Guangzhou, China
-
Research Site
Hangzhou, China
-
Research Site
Inner Mongolia, China
-
Research Site
Nanchang, China
-
Research Site
Qingdao, China
-
Research Site
Shanghai, China
-
Research Site
Shenyang, China
-
Research Site
Taiyuan, China
-
Research Site
Tianjin, China
-
Research Site
Wenzhou, China
-
Research Site
Xi'an, China
-
Research Site
Zhengzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.